Published in J Clin Oncol on March 15, 2002
Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov (2010) 7.48
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev (2013) 3.44
HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev (2009) 2.13
The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine (2012) 1.83
Tumour-targeted nanomedicines: principles and practice. Br J Cancer (2008) 1.81
Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK. Br J Cancer (2003) 1.46
Polymer-drug conjugates: recent development in clinical oncology. Adv Drug Deliv Rev (2008) 1.43
Protease-activated drug development. Theranostics (2012) 1.36
Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem (2008) 1.33
Polymer-drug conjugates: origins, progress to date and future directions. Adv Drug Deliv Rev (2012) 1.28
Polymeric nanomedicine for cancer MR imaging and drug delivery. Chem Commun (Camb) (2009) 1.24
Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased cytotoxicity. Mol Pharm (2010) 1.17
Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles. Pharmacol Rev (2012) 1.15
Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One (2009) 1.15
Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol (2010) 1.11
Nanovehicular intracellular delivery systems. J Pharm Sci (2008) 1.10
Cellular endocytosis and gene delivery. Mol Med (2010) 1.08
Small-molecule delivery by nanoparticles for anticancer therapy. Trends Mol Med (2010) 1.07
Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. J Control Release (2013) 1.06
Advances of cancer therapy by nanotechnology. Cancer Res Treat (2009) 1.01
Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer (2016) 0.99
In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat Biotechnol (2015) 0.98
Endocytic uptake of a large array of HPMA copolymers: Elucidation into the dependence on the physicochemical characteristics. J Control Release (2010) 0.97
Nanoparticles for imaging: top or flop? Radiology (2014) 0.97
Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma. Int J Nanomedicine (2012) 0.96
Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imaging. J Control Release (2014) 0.96
Feasibility of using a bone-targeted, macromolecular delivery system coupled with prostaglandin E(1) to promote bone formation in aged, estrogen-deficient rats. Pharm Res (2008) 0.95
Mannosylated lipid nano-emulsions loaded with lycorine-oleic acid ionic complex for tumor cell-specific delivery. Theranostics (2012) 0.95
Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells. Mol Pharm (2009) 0.95
Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates. Proc Natl Acad Sci U S A (2014) 0.94
Biological rationale for the design of polymeric anti-cancer nanomedicines. J Drug Target (2012) 0.93
Clinical Translation of Nanomedicine. Chem Rev (2015) 0.93
Alternate routes for drug delivery to the cell interior: pathways to the Golgi apparatus and endoplasmic reticulum. Adv Drug Deliv Rev (2007) 0.92
Nanomedical engineering: shaping future nanomedicines. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2014) 0.89
Liposomal delivery of doxorubicin to hepatocytes in vivo by targeting heparan sulfate. Int J Pharm (2009) 0.87
Macromolecular therapeutics. J Control Release (2014) 0.87
Noninvasive Imaging of Nanomedicines and Nanotheranostics: Principles, Progress, and Prospects. Chem Rev (2015) 0.85
Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma. J Histochem Cytochem (2013) 0.83
Targeted delivery system of nanobiomaterials in anticancer therapy: from cells to clinics. Biomed Res Int (2014) 0.83
N-acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers. Biomaterials (2011) 0.82
A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours. Br J Cancer (2004) 0.82
Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review). Int J Oncol (2012) 0.82
Improving aqueous solubility and antitumor effects by nanosized gambogic acid-mPEG₂₀₀₀ micelles. Int J Nanomedicine (2013) 0.79
Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates. Macromol Biosci (2012) 0.79
The Theranostic Path to Personalized Nanomedicine. Clin Transl Imaging (2014) 0.79
Targeting Cathepsin B for Cancer Therapies. Horiz Cancer Res (2015) 0.78
Cellular distribution of injected PLGA-nanoparticles in the liver. Nanomedicine (2016) 0.78
In vitro evaluation of polymeric micelles based on hydrophobically-modified sulfated chitosan as a carrier of doxorubicin. J Mater Sci Mater Med (2012) 0.78
Investigating the effect of tumor vascularization on magnetic targeting in vivo using retrospective design of experiment. Biomaterials (2016) 0.77
Can formulation and drug delivery reduce attrition during drug discovery and development-review of feasibility, benefits and challenges. Acta Pharm Sin B (2014) 0.77
Biopolymer-based delivery systems for advanced imaging and skeletal tissue-specific therapeutics. J Bone Miner Metab (2005) 0.77
Design of smart HPMA copolymer-based nanomedicines. J Control Release (2015) 0.76
Indium-based and iodine-based labeling of HPMA copolymer-epirubicin conjugates: Impact of structure on the in vivo fate. J Control Release (2016) 0.75
A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma. BMC Cancer (2016) 0.75
Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics. Mol Ther Nucleic Acids (2016) 0.75
Multifunctional synthetic poly(L-glutamic acid)-based cancer therapeutic and imaging agents. Mol Imaging (2011) 0.75
Evaluation of pullulan-functionalized doxorubicin nanoparticles for asialoglycoprotein receptor-mediated uptake in Hep G2 cell line. Cancer Nanotechnol (2011) 0.75
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med (2004) 13.34
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet (2007) 9.23
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med (2003) 6.57
Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet (2012) 6.25
Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med (2009) 5.48
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet (2007) 4.68
Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat Genet (2010) 4.20
Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet (2012) 3.19
Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol (2013) 2.90
Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet (2009) 2.59
Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol (2011) 2.55
Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer. PLoS Genet (2011) 2.47
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol (2010) 2.32
Open access chemical and clinical probes to support drug discovery. Nat Chem Biol (2009) 2.28
Improved human embryonic stem cell embryoid body homogeneity and cardiomyocyte differentiation from a novel V-96 plate aggregation system highlights interline variability. Stem Cells (2006) 2.20
Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion (2007) 2.19
Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity (2013) 2.08
Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol (2007) 2.05
Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol (2011) 2.02
Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 2.01
The challenge of cancer control in Africa. Nat Rev Cancer (2008) 1.71
Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med (2010) 1.71
The strong ion gap predicts mortality in children following cardiopulmonary bypass surgery. Pediatr Crit Care Med (2005) 1.68
Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol (2005) 1.57
Mid-term outcomes following endovascular re-intervention for iliac artery in-stent restenosis. Catheter Cardiovasc Interv (2013) 1.56
Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques. J Acquir Immune Defic Syndr (2003) 1.55
Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol (2004) 1.54
The role of cerebral hyperperfusion in postoperative neurologic dysfunction after left ventricular assist device implantation for end-stage heart failure. J Thorac Cardiovasc Surg (2009) 1.52
Heterotrimeric G protein gamma subunits provide functional selectivity in Gbetagamma dimer signaling in Arabidopsis. Plant Cell (2007) 1.51
Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study. J Crit Care (2005) 1.50
"Early" delayed sternal closure following pediatric cardiac surgery. Ann Thorac Surg (2005) 1.50
A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology (2009) 1.46
Exposure to concentrated ambient particles does not affect vascular function in patients with coronary heart disease. Environ Health Perspect (2008) 1.45
Validation of the Kenz Lifecorder EX and ActiGraph GT1M accelerometers for walking and running in adults. Appl Physiol Nutr Metab (2008) 1.45
Arginine methylation controls growth regulation by E2F-1. EMBO J (2012) 1.44
Outcomes following the Kawashima procedure for single-ventricle palliation in left atrial isomerism. Eur J Cardiothorac Surg (2011) 1.43
Sapien 3 Transcatheter Aortic Valve Implantation With Moderate or Without Predilation. J Invasive Cardiol (2016) 1.43
The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty. J Bone Joint Surg Am (2007) 1.42
Angiographic characteristics of femoropopliteal in-stent restenosis: association with long-term outcomes after endovascular intervention. Catheter Cardiovasc Interv (2013) 1.42
Liaison psychiatry for older people--an overlooked opportunity. Age Ageing (2005) 1.42
Self-expanding stent implantation in arterial duct during hybrid palliation of hypoplastic left heart syndrome: midterm experience with a specially designed stent. EuroIntervention (2015) 1.39
The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev (2010) 1.37
Defective mismatch repair in colon cancer: a prognostic or predictive biomarker? J Clin Oncol (2010) 1.34
Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques. J Acquir Immune Defic Syndr (2006) 1.29
Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med (2008) 1.28
Automated, scalable culture of human embryonic stem cells in feeder-free conditions. Biotechnol Bioeng (2009) 1.28
Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res (2007) 1.27
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci U S A (2010) 1.26
Adjuvant chemotherapy for stage II colon cancer: less complicated than we thought. J Clin Oncol (2013) 1.26
A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood (2012) 1.22
Impact of a patient decision aid on care among patients with nonvalvular atrial fibrillation: a cluster randomized trial. CMAJ (2005) 1.22
Guideline for the management of late-life depression in primary care. Int J Geriatr Psychiatry (2003) 1.22
Double-antigen enzyme-linked immunosorbent assay for detection of hepatitis E virus-specific antibodies in human or swine sera. Clin Vaccine Immunol (2008) 1.15
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol (2009) 1.15
Evidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3. J Virol (2006) 1.15
Real time monitoring of risk-adjusted paediatric cardiac surgery outcomes using variable life-adjusted display: implementation in three UK centres. Heart (2013) 1.15
Osteoporosis disease management: What every orthopaedic surgeon should know. J Bone Joint Surg Am (2009) 1.14
Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet (2005) 1.14
Hidden specificity in an apparently nonspecific RNA-binding protein. Nature (2013) 1.13
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol (2011) 1.12
Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway. Oncogene (2002) 1.08
Development of a whole-virus multiplex flow cytometric assay for antibody screening of a specific pathogen-free primate colony. Diagn Microbiol Infect Dis (2005) 1.08
Factors affecting outcome following transplantation of ex vivo expanded limbal epithelium on amniotic membrane for total limbal deficiency in rabbits. Invest Ophthalmol Vis Sci (2002) 1.08
Refinement of the associations between risk of colorectal cancer and polymorphisms on chromosomes 1q41 and 12q13.13. Hum Mol Genet (2011) 1.07
Placebo practice trials: a tool to assess and improve adherence readiness. HIV Clin Trials (2002) 1.05
Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1. J Virol (2011) 1.05
Common culture conditions for maintenance and cardiomyocyte differentiation of the human embryonic stem cell lines, BG01 and HUES-7. Int J Dev Biol (2006) 1.04
Cardiac magnetic resonance imaging after stage I Norwood operation for hypoplastic left heart syndrome. Circulation (2005) 1.02
Consensus conference on vCJD screening of blood donors: report of the panel. Transfusion (2004) 1.02
Capecitabine: have we got the dose right? Nat Clin Pract Oncol (2008) 1.02
Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial. AIDS Res Treat (2012) 1.00
Differential pathogenicity of SHIV infection in pig-tailed and rhesus macaques. J Med Primatol (2008) 1.00
Adjuvant chemotherapy for stage II colorectal cancer: the time is right! Nat Clin Pract Oncol (2005) 0.99
Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. Clin Exp Pharmacol Physiol (2004) 0.99
Comparative study with new accuracy metrics for target volume contouring in PET image guided radiation therapy. IEEE Trans Med Imaging (2012) 0.99
A trial of adjuvant therapy in colorectal cancer: the VICTOR trial. Clin Colorectal Cancer (2003) 0.98
Narrow emission linewidths of positioned InAs quantum dots grown on pre-patterned GaAs(100) substrates. Nanotechnology (2011) 0.98
Chemotherapy side-effect management using mobile phones. Conf Proc IEEE Eng Med Biol Soc (2008) 0.98
Serial magnetic resonance imaging in hypoplastic left heart syndrome gives valuable insight into ventricular and vascular adaptation. J Am Coll Cardiol (2012) 0.98
Atrial septal defect with failure to thrive in infancy: hidden pulmonary vascular disease? Pediatr Cardiol (2002) 0.98
Evaluation of a new rapid immunochromatographic assay for serodiagnosis of acute hepatitis E infection. Am J Trop Med Hyg (2005) 0.97
Auditory cortical activation and speech perception in cochlear implant users: effects of implant experience and duration of deafness. Hear Res (2005) 0.96
A high-sugar/low-fiber meal compared with a low-sugar/high-fiber meal leads to higher leptin and physical activity levels in overweight Latina females. J Am Diet Assoc (2009) 0.95
Exon skipping and gene transfer restore dystrophin expression in human induced pluripotent stem cells-cardiomyocytes harboring DMD mutations. Stem Cells Dev (2013) 0.95
Defective receptor expression and dendritic cell differentiation of monocytes in glioblastomas. Neurosurgery (2006) 0.95
The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. Transfus Med Rev (2010) 0.95
Maintenance of pluripotency in human embryonic stem cells cultured on a synthetic substrate in conditioned medium. Biotechnol Bioeng (2010) 0.94
Comparison of a new immunochromatographic test to enzyme-linked immunosorbent assay for rapid detection of immunoglobulin m antibodies to hepatitis e virus in human sera. Clin Diagn Lab Immunol (2005) 0.94
Targeted therapies: bevacizumab--has it reached its final resting place? Nat Rev Clin Oncol (2011) 0.93
Bridging the gap between primary and secondary care: use of a clinical pathway for the investigation and management of deep vein thrombosis. J Health Serv Res Policy (2008) 0.93
Optimization of the injected activity in dynamic 3D PET: a generalized approach using patient-specific NECs as demonstrated by a series of 15O-H2O scans. J Nucl Med (2009) 0.93
Guidance on the transport of laboratory animals. Lab Anim (2005) 0.93
Use of a protocolized approach to the management of sepsis can improve time to first dose of antibiotics. J Crit Care (2012) 0.92
EnROL: a multicentre randomised trial of conventional versus laparoscopic surgery for colorectal cancer within an enhanced recovery programme. BMC Cancer (2012) 0.92
Primary obturator externus pyomyositis in a child presenting as hip pain: a case report. Pediatr Emerg Care (2008) 0.92